Pfizer/BioNTech Strike COVID-19 Manufacturing Deal With Biovac For South Africa

Pfizer Inc PFE and BioNTech SE BNTX have struck a deal with South Africa's Biovac Institute to process and distribute over 100 million doses a year of their COVID-19 vaccine for the African Union beginning in 2022.
Technical transfer, on-site development, and equipment installation activities will begin immediately.
Biovac is a public-private partnership focused on vaccine production.
It will receive COVID-19 vaccine drug substance made in Europe's plants and begin fill-finish operations in 2022.
Price Action: BNTX stock is up 1.70% at $249.35, while PFE shares are down 1.40% at $40.59 during the market session on the last check Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.